EP2121715A4 - Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof - Google Patents

Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof

Info

Publication number
EP2121715A4
EP2121715A4 EP08725693A EP08725693A EP2121715A4 EP 2121715 A4 EP2121715 A4 EP 2121715A4 EP 08725693 A EP08725693 A EP 08725693A EP 08725693 A EP08725693 A EP 08725693A EP 2121715 A4 EP2121715 A4 EP 2121715A4
Authority
EP
European Patent Office
Prior art keywords
metastasis
migration
blocking
cancer cells
new compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08725693A
Other languages
German (de)
French (fr)
Other versions
EP2121715A1 (en
Inventor
Pui-Kwong Chan
May Sung Mak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacific Arrow Ltd
Original Assignee
Pacific Arrow Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/683,198 external-priority patent/US8614197B2/en
Priority claimed from PCT/US2007/077273 external-priority patent/WO2008028060A2/en
Application filed by Pacific Arrow Ltd filed Critical Pacific Arrow Ltd
Publication of EP2121715A1 publication Critical patent/EP2121715A1/en
Publication of EP2121715A4 publication Critical patent/EP2121715A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
EP08725693A 2007-02-16 2008-02-15 Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof Withdrawn EP2121715A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89038007P 2007-02-16 2007-02-16
US11/683,198 US8614197B2 (en) 2003-10-09 2007-03-07 Anti-tumor compounds with angeloyl groups
US94770507P 2007-07-03 2007-07-03
PCT/US2007/077273 WO2008028060A2 (en) 2006-09-01 2007-08-30 Anti-tumor compounds for inhibiting cancer growth
PCT/US2008/002086 WO2008133766A1 (en) 2007-02-16 2008-02-15 Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof

Publications (2)

Publication Number Publication Date
EP2121715A1 EP2121715A1 (en) 2009-11-25
EP2121715A4 true EP2121715A4 (en) 2010-12-29

Family

ID=39925959

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08725693A Withdrawn EP2121715A4 (en) 2007-02-16 2008-02-15 Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof

Country Status (7)

Country Link
EP (1) EP2121715A4 (en)
JP (1) JP2010519219A (en)
CN (1) CN101772511A (en)
AU (1) AU2008244648A1 (en)
CA (1) CA2676791A1 (en)
SG (1) SG178795A1 (en)
WO (1) WO2008133766A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727561B2 (en) 2001-08-31 2010-06-01 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7524824B2 (en) 2003-09-04 2009-04-28 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7488753B2 (en) 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
US7514412B2 (en) 2003-10-09 2009-04-07 Pacific Arrow Limited Anticancer biangeloyl saponins
US8614197B2 (en) 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US8586719B2 (en) 2005-04-27 2013-11-19 Pacific Arrow Limited Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
US20120277308A1 (en) 2010-07-16 2012-11-01 Pacific Arrow Limited compounds for treating cancer and other diseases
CN115197293A (en) * 2010-07-16 2022-10-18 太平洋艾瑞有限公司 Novel compounds useful for the treatment of cancer and other diseases
KR101398079B1 (en) * 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin
KR101403019B1 (en) 2013-02-25 2014-06-03 서울대학교산학협력단 Novel biomarker for the diagnosis of lung cancer
KR20150122786A (en) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) Method for the diagnosis, prognosis and treatment of cancer metastasis
CN103235141A (en) * 2013-04-27 2013-08-07 上海交通大学医学院附属新华医院 Application of ATF (activating transcription factor) 3 to predicting bladder cancer metastasis and judging prognosis
JP6339814B2 (en) * 2014-02-05 2018-06-06 株式会社島津製作所 Cancer metastasis marker and analysis method thereof
CN104502603B (en) * 2014-12-03 2016-04-06 上海交通大学医学院附属上海儿童医学中心 MYO1D closes or open mark as diagnosis arterial duct
EP3229909B1 (en) 2014-12-11 2020-10-14 Inbiomotion S.L. Binding members for human c-maf
CN105061545B (en) * 2015-08-17 2018-01-30 中国人民解放军第二一〇医院 Triterpene saponin componds and its preparation method and application in shiny-leaved yellowhorn
US10167293B2 (en) * 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CN106947821B (en) * 2017-04-11 2020-06-30 成都望路医药技术有限公司 Biomarkers for diagnosis and treatment of colon adenocarcinoma
CN108410986B (en) * 2018-02-26 2021-06-22 中国人民解放军总医院 CDH6 promotes osteosarcoma growth and metastasis
CN110272997B (en) * 2018-03-14 2023-04-28 华中科技大学同济医学院附属同济医院 Application of C/EBP beta gene or protein
KR102128331B1 (en) * 2018-04-30 2020-06-30 인하대학교 산학협력단 Composition for suppressing cancer metastasis into aged vascular endothelial cell by radiation-induced, comprising suppressor of CDH13 or gene encoding the same
CN109970839B (en) * 2019-04-16 2022-03-01 沈阳药科大学 Triterpenoid saponin compound and preparation method and medical application thereof
CN110672848A (en) * 2019-10-25 2020-01-10 四川大学华西医院 Application of APEH autoantibody detection reagent in preparation of lung cancer screening kit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037200A2 (en) * 2003-10-09 2005-04-28 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
WO2005063273A1 (en) * 2003-12-23 2005-07-14 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
WO2006029221A2 (en) * 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2006116656A2 (en) * 2005-04-27 2006-11-02 Pacific Arrow Limited Compositions comprising triterpene saponins and compounds with functional angeloyl groups for inhibition of venous insufficiency, leg swelling and tumors
WO2008028060A2 (en) * 2006-09-01 2008-03-06 Pacific Arrow Limited Anti-tumor compounds for inhibiting cancer growth

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616943B2 (en) * 2001-08-31 2003-09-09 Fountain Silver Limited Composition comprising Wenguanguo extracts and methods for preparing same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037200A2 (en) * 2003-10-09 2005-04-28 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
WO2005063273A1 (en) * 2003-12-23 2005-07-14 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
WO2006029221A2 (en) * 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2006116656A2 (en) * 2005-04-27 2006-11-02 Pacific Arrow Limited Compositions comprising triterpene saponins and compounds with functional angeloyl groups for inhibition of venous insufficiency, leg swelling and tumors
WO2008028060A2 (en) * 2006-09-01 2008-03-06 Pacific Arrow Limited Anti-tumor compounds for inhibiting cancer growth

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AHN KYUNG-SEOP ET AL: "Effects of oleanane-type triterpenoids from fabaceous plants on the expression of ICAM-1", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 25, no. 8, August 2002 (2002-08-01), pages 1105 - 1107, XP002609400, ISSN: 0918-6158 *
CHEMICAL AND PHARMACEUTICAL BULLETIN (TOKYO), vol. 48, no. 11, November 2000 (2000-11-01), pages 1711 - 1719, ISSN: 0009-2363 *
CHINESE JOURNAL OF LUNG CANCER 200308 CN, vol. 6, no. 4, August 2003 (2003-08-01), pages 254 - 257, ISSN: 1009-3419 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2004, OVESNA Z ET AL: "Pentacyclic triterpenoic acids: new chemoprotective compounds", XP002609502, Database accession no. PREV200500050812 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2000 (2000-11-01), TEZUKA YASUHIRO ET AL: "Constituents of the Vietnamese medicinal plant Orthosiphon stamineus", XP002609401, Database accession no. PREV200100067220 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; August 2003 (2003-08-01), HUANG W ET AL: "Study on anti-invasive effect and apoptosis induction of pentacyclic triterpenoid in human lung cancer cells", XP002609399, Database accession no. EMB-2003347021 *
KONOSHIMA T ET AL: "ANTITUMOR AGENTS 82. CYTOTOXIC SAPOGENOLS FROM AESCULUS-HIPPOCASTANUM", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 49, no. 4, 1 July 1986 (1986-07-01), pages 650 - 656, XP002510554, ISSN: 0163-3864, DOI: 10.1021/NP50046A015 *
NEOPLASMA (BRATISLAVA), vol. 51, no. 5, 2004, pages 327 - 333, ISSN: 0028-2685 *
See also references of WO2008133766A1 *
VOUTQUENNE L ET AL: "Haemolytic acylated triterpenoid saponins from Harpullia austro-caledonica", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 66, no. 7, 1 April 2005 (2005-04-01), pages 825 - 835, XP004846755, ISSN: 0031-9422, DOI: 10.1016/J.PHYTOCHEM.2005.02.009 *

Also Published As

Publication number Publication date
WO2008133766A1 (en) 2008-11-06
CN101772511A (en) 2010-07-07
JP2010519219A (en) 2010-06-03
CA2676791A1 (en) 2008-11-06
AU2008244648A1 (en) 2008-11-06
EP2121715A1 (en) 2009-11-25
SG178795A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
EP2121715A4 (en) Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
EP2254899A4 (en) Blocking the metastasis of cancer cells and the uses of new compounds thereof
EP2436696B8 (en) Anti-beta-amyloid antibody and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
EP2223969A4 (en) Resin composition, transparent member obtained from the resin composition, and use of the same
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
DE602008004795D1 (en) Conductive materials
DE602008005212D1 (en) Metallic, double-sided element and zipper
HK1130489A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2211354A4 (en) Coated conductive powder and conductive adhesive using the same
EP1931733A4 (en) Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
HK1144556A1 (en) Inhibition of tumor metastasis by anti-neuropilin antibodies
EP2116574A4 (en) Composition containing pyrimidine compound and luminescent element employing the composition
EP2241613A4 (en) Fluid receiving cartridge and utilization of the same
SE0601195L (en) Ways of manufacturing agglomerated cemented carbide or cermet powder mixtures
EP2128249A4 (en) Zinc oxide-binding antibody and use thereof
PL2179073T3 (en) Al-Ti-Ru-N-C HARD MATERIAL COATING
HK1121588A1 (en) Improved seal assembly for battery and the battery using the same
AU2009213453A8 (en) Anti-ADAM-15 antibodies and utilization of the same
EP2184793A4 (en) Switching element and application of the same
GB0701728D0 (en) Assays and therapy
EP2243773A4 (en) Platinum complex compound and utilization of the same
IL205405A0 (en) Polypeptide compound, composition comprising the same and use thereof
AU2007903494A0 (en) Modulation of Pericyte Migration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAK, MAY, SUNG

Inventor name: CHAN, PUI-KWONG

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136301

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20101117BHEP

Ipc: A61K 31/704 20060101AFI20101117BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101126

17Q First examination report despatched

Effective date: 20131018

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140301

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1136301

Country of ref document: HK